Beactica announces drug discovery agreement with Cubist Pharmaceuticals

Beactica AB, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ: CBST). Under the agreement, Beactica will use its surface plasmon resonance (SPR)-integrated drug discovery platform to target multi-component proteins from pathogenic bacteria of interest to Cubist. Financial terms of the agreement were not disclosed.

"We are pleased to be working with Cubist in their quest to develop next-generation anti-bacterials” said Beactica CEO, Dr Per Källblad. "Cubist has excellent strengths in the area and it is a source of pride to have been selected to help progress one of their discovery programmes.”

Cubist becomes the fifth life-science company to enter an agreement with Beactica in the past eighteen months.

For further information, please contact Dr Per Källblad, CEO Beactica, +46 (0)18 56 08 80.

More News